Amgen Inc. (AMGN) News Nov 18, 2014, 6:17 p.m. MarketWatch

New Post Public Reply Private Reply Replies (0) Message Board

Nov 18, 2014 at 9:38 PM

Amgen Inc. (AMGN) News Nov 18, 2014, 6:17 p.m.
MarketWatch News on AMGN
Amgen's stock drops after trial misses secondary endpoint 9:20 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen's stock drops 2% in premarket trade 9:07 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen study on cancer treatment misses secondary endpoint 9:06 a.m. Nov. 4, 2014 - Tomi Kilgore
Facebook, Gilead shares fall after hours 6:14 p.m. Oct. 28, 2014 - Sue Chang
Amgen, under investor pressure, outlines strategy 10:05 a.m. Oct. 28, 2014 - MarketWatch.com
Amgen's stock rises after company outlines capital allocation plans 9:07 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen's stock climbs 3.2% in premarket trade after capital allocation plans 8:55 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 revenue $20.8 bln-$21.3 bln vs. FactSet consensus $20.33 bln 8:54 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 adj. EPS $9.05-$9.40 vs. FactSet consensus $9.08 8:53 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to payout 60% of adj. earnings to shareholders through 2018 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to raise dividend 30% starting in Q1 2015 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen resumes share buybacks, with plans for $2 bln in repurchases through 2015 8:51 a.m. Oct. 28, 2014 - Tomi Kilgore
‘Dumb money’ unloads bullish oil bets as prices pose threat to stocks 8:35 a.m. Oct. 28, 2014 - Shawn Langlois
4 more ‘Amazon’ stocks you may want to avoid 8:43 p.m. Oct. 27, 2014 - Philip van Doorn
Newscast: Stocks mixed -- barely 6:46 p.m. Oct. 27, 2014 - MarketWatch
Twitter shares drop in wake of quarterly results 5:07 p.m. Oct. 27, 2014 - Sue Chang
Amgen posts strong results on higher sales 4:57 p.m. Oct. 27, 2014 - MarketWatch.com
Updates, advisories and surprises 4:31 p.m. Oct. 27, 2014 - MarketWatch
Amgen net drops, but adjusted earnings beat views 4:14 p.m. Oct. 27, 2014 - Russ Britt
Amgen GAAP net of $1.61 is below $1.81 view 4:06 p.m. Oct. 27, 2014 - Russ Britt
Loading more headlines...
Advertisement
Other News on AMGN
Gilead's Value Without Its Hep C Franchise 4:07 p.m. Today - Seeking Alpha
Zetia Shows Modest Benefit in Reducing Heart Attacks 5:26 p.m. Nov. 17, 2014 - The Wall Street Journal Interactive Edition
Merck Drug Works: Vytorin Study Proves Successful 12:35 p.m. Nov. 17, 2014 - Investors Business Daily
3 Stocks Moving The Drugs Industry Upward 12:03 p.m. Nov. 17, 2014 - TheStreet.com
Jana Partners 13F Filing Shows Moves In Alibaba & Other Big Names 10:34 a.m. Nov. 14, 2014 - benzinga.com
Regeneron Pharmaceuticals Offers More Upside Than Gilead Sciences 9:23 a.m. Nov. 14, 2014 - Seeking Alpha
AstraZeneca/Amgen's Brodalumab Positive in Psoriasis Trial - Analyst Blog 5:10 p.m. Nov. 13, 2014 - Zacks.com
Amgen Shares Consolidating Ahead Of More Gains? 12:25 p.m. Nov. 13, 2014 - benzinga.com
3 Stocks Underperforming Today In The Drugs Industry 12:06 p.m. Nov. 13, 2014 - TheStreet.com
ARNA Management And Investors Underestimating The Potential Of Belviq And Phentermine Combination 9:52 a.m. Nov. 13, 2014 - Seeking Alpha
10 Must-Own Stocks With Great Earnings, Sales and Guidance 12:15 a.m. Nov. 13, 2014 - InvestorPlace.com
3 Stocks Reiterated As A Buy: CMCSA, MO, AMGN 1:44 p.m. Nov. 12, 2014 - TheStreet.com
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog 8:48 a.m. Nov. 12, 2014 - Zacks.com
UPDATE: Deutsche Bank Reiterates On Amgen On Potential Of New Drugs 8:17 a.m. Nov. 12, 2014 - benzinga.com
Biotech Short Interest Becomes Stock Specific 8:11 a.m. Nov. 12, 2014 - 247WallSt.com
Earnings Triple Plays 2:54 a.m. Nov. 12, 2014 - Seeking Alpha
Amgen's brodalumab beats Stelara in Phase 3 trial 4:52 p.m. Nov. 11, 2014 - Seeking Alpha
Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3:03 p.m. Nov. 11, 2014 - benzinga.com
Amgen Fights To Protect Neupogen's Exclusivity 12:31 p.m. Nov. 11, 2014 - Seeking Alpha
NPS Pharmaceuticals Incurs Wider Q3 Loss, Revenues Miss - Analyst Blog 11:50 a.m. Nov. 11, 2014 - Zacks.com
Loading more headlines...
Press Releases on AMGN
Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels 4:00 p.m. Today - PR Newswire - PRF
Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza 4:05 p.m. Nov. 17, 2014 - GlobeNewswire
Amgen To Present At The Jefferies Global Healthcare Conference 4:15 p.m. Nov. 14, 2014 - PR Newswire - PRF
Critical Alerts For Caesars Entertainment, Orexigen Therapeutics, Amazon.com, Toyota Motor and Amgen Released By InvestorsObserver 9:31 a.m. Nov. 13, 2014 - PR Newswire - PRF
Biothera Names Carey Anderson VP of Regulatory Affairs 9:30 a.m. Nov. 13, 2014 - BusinessWire - BZX
Amgen To Webcast Investor Call At Upcoming American Heart Association Scientific Sessions 4:35 p.m. Nov. 12, 2014 - PR Newswire - PRF
Amgen To Highlight New Data For Investigational Cholesterol-Lowering Medication Evolocumab 4:01 p.m. Nov. 12, 2014 - PR Newswire - PRF
The Amgen Foundation Expands Amgen Scholars Program to 17 Top Educational Institutions Worldwide 9:00 a.m. Nov. 12, 2014 - PR Newswire - PRF
Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4:01 p.m. Nov. 11, 2014 - PR Newswire - PRF
Melanoma Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth 2:24 p.m. Nov. 10, 2014 - PR Newswire - PRF
VYCOR: "On the Cusp of the Next Big Healthcare Trend" 9:23 a.m. Nov. 10, 2014 - ACCESSWIRE
FDA Accepts Amgen's Biologics License Application For LDL Cholesterol-Lowering Medication Evolocumab 9:15 a.m. Nov. 10, 2014 - PR Newswire - PRF
Ziarco Raises $33.1 Million in Series B Financing 7:01 a.m. Nov. 10, 2014 - GlobeNewswire
Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA 8:50 a.m. Nov. 7, 2014 - PR Newswire - PRF
Amgen To Present At The Credit Suisse Annual Healthcare Conference 4:30 p.m. Nov. 6, 2014 - PR Newswire - PRF
Amgen Highlights New Data In The Treatment Of Blood Cancers At ASH 2014 4:01 p.m. Nov. 6, 2014 - PR Newswire - PRF
Cloud Pharmaceuticals Announces World-Class Board of Directors 8:00 a.m. Nov. 5, 2014 - PR Newswire - PRF
Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3 Trebananib TRINOVA-1 Trial In Patients With Recurrent Ovarian Cancer 9:00 a.m. Nov. 4, 2014 - PR Newswire - PRF
Karyopharm Appoints J. Scott Garland to Its Board of Directors 7:00 a.m. Nov. 4, 2014 - GlobeNewswire
3D Bioprinting Technology Developed by RBCC Partner n3D Biosciences Helps Researchers Create a Better In Vitro Breast Cancer Model 5:30 a.m. Nov. 3, 2014 - BusinessWire - BZX
Loading more headlines...

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

EMCO's New Automated Facility Could Shake Industry

A Novel Leap in Production Capacity EMCO Industries just put a solid foot on the accelerator with their brand-new, shiny, fully automated plant over in Claremore, Oklahoma. If you're glancing at heavy-duty trailer springs, you can't ignore the fact that this is a multimillion-dollar investment. Heck, this monstrous 30,000-square-foot facility more than doubles what EMCO...

Gong, Agentforce, Avoma Crowned 2026 CI Champions

Diving Deep into Conversation Intelligence There's a lot to unpack when three software titans hog the spotlight, and that's exactly what's happening in the world of conversation intelligence this year. It's like we've hit the jackpot with Gong, Agentforce Sales, and Avoma carving out their turf as the 2026 Champions, according to the venerable Info-Tech Research Group....

U. of Phoenix and LACCD Launch 3+1 Degree Pathway

Opening the Floodgates for Ambitious Community College Students When it comes to climbing the educational ladder, not everyone starts at the same rung. That's a fact we've all come to terms with in one way or another. Enter the University of Phoenix and the Los Angeles Community College District with a solution to expand educational access. The 3+1 Program: A Cost-Saving...

Ornellaia's 2026 Harvest: Adapting to Nature's Whims

A Year Marked by Weather's Unpredictable Dance Nobody said making wine was a walk in the park, and the folks at Ornellaia know better than most how to roll with whatever nature throws their way. The 2026 harvest story is as much about unlocking the secrets of the soil as it is about navigating the quirks of the weather. Situated in Bolgheri, Italy, this year's vintage...

C3EL Expands Federal Footprint with Strategic Contracts

Pushing Boundaries in Federal Contracts What a ride C3EL's had in Government Fiscal Year 2026! Let me tell you, they’ve bagged a bunch of contracts that’d make any company’s mouth water. Kicking things off, they snagged a prime cybersecurity contract from the U.S. Air Force. Considering our current cybersecurity landscape, that's like striking gold. But they...

Duke Energy's Cost-Protection Plan Shields Ratepayers

Shielding Customers From Data Center Costs Let's get right into the thick of it: Duke Energy's latest move is a strategic one, shrouded in industry terms but with a real impact on regular folks' wallets. The company's agreement with heavyweights like Amazon, Google, and Meta aims to protect existing customers in North Carolina from getting hit with the costs of powering...

Merit Expands in New York with Bold Acquisition Move

Merit Financial's Growth Trajectory Takes a Leap You watch the movers and shakers in this game long enough, and you start to see patterns. Merit Financial Advisors is one of those juggernauts you'd better keep an eye on. These folks just scooped up Moldenhauer & Associates—a firm that's been a staple in Orchard Park, New York—for a cool $1.1 billion worth of client...

Decoding CarBravo-Certified vs Traditional Used Cars

What’s Behind Door Number One: CarBravo Certification When you walk onto a car lot these days, it's a mixed bag: shiny badges boasting certifications or basic used car signage. For anyone who's spent time around cars, two types stick out—there’s your CarBravo-certified vehicles and your good ol' used cars. Now, Marissa McCoy and Jill Maniaci from Heidebreicht...

HelloNation Brings 'Edvertising' to NC REALTORS® Event

HelloNation's Bold Step into Real Estate Networking October 8th to the 11th is shaping up to be a pivotal few days in Wilmington, North Carolina. Here’s the scoop: HelloNation, known for its innovative 'edvertising' model, is joining the bustling crowd at the 2026 NC REALTORS® Convention. This isn’t just any get-together—it's the grandest annual jamboree for real...

Wally Disrupts Dental Industry with $25M Funding

A New Breath of Fresh Air for Dental Care Dental visits—a tedious, costly affair we've all dreaded. So, when Wally rolls out an overhaul in this stale landscape, it's worth taking notice. With $25 million in their pockets from Series A funding led by Maveron, Wally's swaggering in with a plan to flip the script on dental care across the nation. Redefining the Dental...